Home › Groups › Pharmacy Learning Network ›

Home

Save the Date!

REGISTER NOW for PLN Philadelphia on March 30-31!

Earn up to 10 contact hours over 2 exciting days, starting with a half-day of dedicated oncology pharmacy education!

Pharmacy Learning Network provides Health-System Pharmacists with live, local learning across the United States—see our complete 2012 schedule and mark your calendar!

 

New for 2012—PLN Oncology!

Select cities will have the opportunity to attend a half day of education focused solely on oncology pharmacy topics, in conjunction with full-day Pharmacy Learning Network conferences. Read More

Setting the Standard for Health-System Pharmacist Education

Pharmacy Learning Network (PLN) provides a complete educational experience, specifically targeted to health-system pharmacists. Live regional Pharmacy Learning Network conferences, held nation-wide, offer interactive education in a live setting, followed by sequential web-based programming. This learner-driven, long-term educational method ensures that health-system pharmacists are provided with the knowledge and practical application strategies to implement beneficial changes within their facility.

Interested in Improving Hemostatic Practices at Your Facility?

In the newest PLN CE Newsletter, Drs. Michael Gabay and Robert MacLaren strategize how to institute optimal hemostatic practices in the surgical setting and increase pharmacy oversight of hemostatic agents.

 

CLICK HERE TO READ MORE

Ask A PLN Expert!

Have a question on dosages or drug interactions? Facing a challenge and would like the input of a Pharmacy Learning Network faculty member? Click here to ask your question and a Pharmacy Learning Network hospital pharmacy expert will reply!

Ask A Question Now »

News View More

  • ROCKET-AF Subanalysis: Intracranial Hemorrhage Risk Higher with Warfarin than Rivaroxaban
    02/3/12
    Compared with warfarin, the new-generation anticoagulant rivaroxaban was associated with a 40% lower risk of intracranial hemorrhage in patients with atrial fibrillation who were taking the agents to prevent stroke. Read More »
  • Investigational Androgen Receptor Boosts Survival in Advanced Prostate Cancer
    02/1/12
    An investigational androgen receptor antagonist substantially boosts survival in castration-resistant prostate cancer, phase III trial results showed. Read More »
  • Antidotes to New Anticoagulants Needed for Trauma Setting
    01/27/12
    LAKE BUENA VISTA, FLA. – Patients on one of the powerful new oral anticoagulants are left without a good antidote for bleeding if they experience a traumatic injury. The use of these agents is climbing as baby boomers age and the number of patients with atrial fibrillation continues its steady rise from 2.0 million in 1995 to a projected 4.34 million by 2030. Read More »